Policy Decoded Newsletter via the New York Times
| What Happened: New York’s Office of Cannabis Management filed administrative charges Monday seeking to revoke Omnium Health’s manufacturing and distribution licenses, impose at least $1 million in fines, and ban the Long Island processor from the state for allowing unlicensed out-of-state brands to manufacture products at its facilities without obtaining required Type 3 Brand Licenses. The charges followed an eight-month investigation showing Omnium collected rent and royalties from brands including Stiiizy, Mfused, and Grön while passing off their manufacturing as its own work, bypassing New York’s requirement that even brands using white-label arrangements must become licensed. OCM ordered a $30 million recall of products made at Omnium facilities and said the investigation remains active with additional cases potentially filed against the brands that used the scheme. Between January and August, the 17 brands using Omnium’s unlicensed arrangement generated $65 million in sales representing 6.2 percent of New York’s $1 billion market, with most products already sold to consumers during the 4/20 rush before regulators moved. State law allows penalties of three to five times retail value of products, which could produce fines far exceeding the proposed $1 million baseline and set a record for the agency. |
| Why It Matters: Legitimate business practices like co-packing and white labeling just became compliance minefields where paperwork determines legality rather than product safety. New York created the Type 3 Brand License specifically to allow out-of-state brands to license their IP and enter white-label agreements with New York processors without becoming True Parties of Interest or operating facilities, recognizing that co-packing is standard industry practice. The violation here was operating without that license, but the compliance line is razor-thin: brands licensing IP while attempting to avoid individual licensure state-by-state can easily cross from permitted white labeling into prohibited reverse licensing depending on contract structure and control provisions. Regulators can spot this through batch records and equipment capacity analysis, but proving it in administrative hearings when brands claim compliant white-label agreements is considerably harder. OCM saying products were likely safe despite Omnium’s inability to provide complete manufacturing records means enforcement is about market structure protection rather than consumer safety. Interstate commerce would eliminate these gymnastics entirely, but federal prohibition forces brands into state-by-state licensing arrangements that create grey areas sophisticated operators exploit. |
